Sunday, June 1, 2025

Latest

Trulieve Sees Margins Contract, Expenses Climb In Q4 Following Harvest Acquisition

Trulieve Cannabis (CSE: TRUL) reported its fourth quarter and full year financial results for 2021 this morning, posting quarterly revenue of $305.3 million. The company meanwhile posted a net loss for the period, despite the record quarterly sales figure.

Revenue improved 36% on a quarter over quarter basis, climbing from $224.1 million in the third quarter to $305.3 million in the fourth quarter. Despite the massive bump in topline results, the company managed to post declining gross profit on a sequential basis, with gross profits falling from $153.9 million to $132.4 million, a 14% decrease. Gross margin % as a result fell from 69% to that of 43%.

Operating expenses grew rather significantly as well, jumping from $87.7 million to $150.6 million, a 72% increase, and the result of the Harvest Health acquisition closing on October 1. This in turn lead to the company posting a net loss of $71.5 million for the fourth quarter, as compared to an $18.6 million net income in the third quarter. Adjusted EBITDA meanwhile came in at $100.9 million, as compared to $98.0 million in Q3.

For the full fiscal year, revenues rose to $938.4 million, up 80% from $521.5 million seen in 2020. Gross profit was up 47% to $566.1 million, while gross margins were impacted heavily, falling from 74% to 60%. The decline was blamed on “strategic diversification,” with the company moving into lower margin channels and markets.

Despite the significant topline improvement, net income fell 71% on a year over year basis, dropping from $63.0 million to $18.0 million in 2021. Adjusted EBITDA meanwhile improved 48% on an annual basis to $384.6 million.

The company also reported a cash position of $234 million as of December 31, 2021.

In terms of guidance, Trulieve expects revenue for 2022 to be between $1.3 and $1.4 billion, while adjusted EBITDA is expected to come in at between $450 and $500 million. The company also indicated that it expects the second half of the year to have a stronger financial performance than the first half.

Full financial results have yet to be filed as of the time of writing.

Trulieve Cannabis last traded at $25.88 on the CSE.


Information for this briefing was found via Sedar and Trulieve Cannabis. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

Solaris Resources: The Royal Gold Financing Package

How a Single Deal Turned 2 ‘Dead’ Mines into a $2B Project | Canadian Copper PEA – Simon Quick

Silver47 x Summa Silver: Creating An Explorer With A Billion Ounce Goal

Recommended

Brazil Potash Completes Site Prep For Port Terminal

Silver47 x Summa Silver: Creating An Explorer With A Billion Ounce Goal

Related News

Trulieve’s Net Losses In Q3 2022 Widened By Five Times

The cannabis firm sees revenue down sequentially while inventories are on an upward trend. Trulieve...

Thursday, November 10, 2022, 03:14:00 PM

Trulieve Records $120.8 Million In Revenue In Q2, Net Income of $6.6 Million, Raises Guidance

Trulieve Cannabis Corp (CSE: TRUL) reported its second quarter 2020 earnings this morning, reporting record...

Wednesday, August 12, 2020, 07:53:43 AM

Trulieve Q4 2023 Financials: 4% Revenue Drop, Narrowed Losses

Trulieve Cannabis (CSE: TRUL) has released its financial results for the fourth quarter and full...

Thursday, February 29, 2024, 02:05:05 PM

Trulieve Director Sells $5.7 Million Worth Of Shares

Trulieve Cannabis (CSE: TRUL) has seen a plethora of insider transactions filed with Sedi over...

Friday, September 4, 2020, 10:01:10 AM

Trulieve: Analysts Expect Beat On Company Full Year Guidance

Trulieve Cannabis (CSE: TRUL) announced that they will be reporting their fourth quarter and year-end...

Friday, March 5, 2021, 10:37:00 AM